Moringa Acquisition (MACA) 10-K2023 FY Annual report

Filed: 1 Apr 24, 4:05pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll. sophomore Avg

New words: abovementioned, antitrust, attack, Awarded, backstop, BCA, biotech, border, bore, cabinet, campaign, chance, civilian, cloud, confirmation, consecutive, constrain, convince, cybersecurity, deliberate, duration, East, empowered, enjoining, Erroneously, freely, Gaza, Headquartered, hearing, hostile, hundred, illegal, incident, inclusion, infiltrated, infrastructure, injunction, instructed, intervention, inverse, kidnapping, left, lengthy, macroeconomic, MAP, military, misappropriation, missile, mitigating, mutated, neighboring, nonassessable, October, Offshore, oncogene, parallel, partial, pharma, pharmaceutical, proprietary, quotient, Red, retirement, rocket, RSU, Sea, Segregated, settled, shown, Silexion, solid, sophisticated, Strip, successor, supposed, suspension, Taxation, terror, terrorism, thirty, tort, tumor, twenty, unsatisfactorily, usable, vested, vesting, voluntarily, war, Westport, wholly, withdrew, Yakira

Removed: acceptable, advent, approach, ascribed, automatic, behavior, blurring, Bribery, capitalization, cent, contemplate, convergence, Corrupt, cultural, cumulative, demonstrate, dilutive, diminish, disparate, disruption, disruptive, downturn, drafting, drawn, excluded, failing, fit, geographically, hinder, impairment, indefinite, intellectual, intensify, issuing, language, list, lower, measuring, media, omission, preliminary, receivable, recognizing, regime, rendering, resign, restructure, retail, Saba, Shekel, slower, staffing, step, succeed, suspected, timeframe, transparency, travel, treat, ultimate, underdeveloped, uneven, unpaid, unpredictable, unrest, upheaval, windup, withholding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MACA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b)/RULE 15d-14(b) UNDER THE EXCHANGE ACT

AND 18 U.S.C. § 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Moringa Acquisition Corp (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Ilan Levin, Chairman and Chief Executive Officer of the Company, and Gil Maman, Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: April 1, 2024

/s/ Ilan Levin
Ilan Levin
Chairman and Chief Executive Officer
(Principal Executive Officer)

/s/ Gil Maman
Gil Maman
Chief Financial Officer
(Principal Financial and Accounting Officer)

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.